| External factors: | Apremilast |
| Aging type: | Prevent |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Osteoarthritis |
| Experiment: | SA-β-gal activity assay |
| Description: | IL-17 stimulation induced a 3.7-fold increase of SA-β-gal activity, while 1 ?M apremilast reduced its activity to only 2.1-fold |
| Target gene: | SIRT1 |
| R-EF-Target gene: | Upregulation |
| Official symbol(s): | SIRT1 |
| Target gene experiment: | RT-qPCR//Western blot |
| Target gene description: | Compared to the non-treated cells, IL-17 reduced the mRNA level of SIRT1 to 53%, which was recovered to 92%, close to the baseline, in the presence of 1 ?M apremilast. It was also confirmed that apremilast rescued the protein level of SIRT1 which had been significantly reduced by IL-17. As revealed in Fig. 7A, in normal SIRT-expressing cells, apremilast significantly suppressed cellular senescence, however, its effect was almost abolished in SIRT1-silenced cells. The results from western blot analysis in Fig. 7B and C revealed that the inhibitory effect of apremilast on PAI-1 and p21 was abolished by the silencing of SIRT1. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: